AVBPArriVent BioPharma, Inc.

Healthcare
$16.72-5.3% 1Y

Price

-5.3%1Y

End-of-day closes, not the intraday tick.

The five questions

2 of 5 available

Only two of the five can be answered for AVBP today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

  • Is the business good?not enough filed
  • Is it safe?Watch
  • Is the price fair?not enough filed
  • Is it growing?not enough filed
  • What is the market doing?Mixed
What they do

We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. We seek to utilize our team’s deep drug development experience to maximize the potential of our lead product candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, including ARR-217 (MRG007), through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

In the company’s own words · 10-K filed Mar 5, 2026 · SEC EDGAR

P/En/a
Market value$1.58B
1 year-5.3%
5 yearsn/a

Charts

As reported to the SEC, without any scoring.

The next results filing is expected around Nov 9, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

  1. Oct 6, 2026The information set forth in the press release referred to in.Regulation FD disclosure · Form 8-K
  2. Aug 12, 2026On August 11, 2026, ArriVent BioPharma, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Allist License Agreement”) with Shanghai Allist Pharmaceuticals Co., Ltd. (“Allist”), a pharmaceutical company incorporated under the laws of China.Material agreement entered · Form 8-K
  3. May 11, 2026On May 11, 2026, ArriVent BioPharma, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a prospectus supplement (the “Prospectus Supplement”), dated May 11, 2026, with respect to the Company’s existing “at the market offering” program (the “ATM Program”)Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.

On our screens:Most shorted stocks

Biotechnology

The closest names by size in the same industry

Compare peers
ZBIO+3.7%
Zenas BioPharma, Inc.
SEPN+3.9%
Septerna, Inc.
IMCR+1.1%
Immunocore Holdings plc
ARDX+0.46%
Ardelyx, Inc.
MAZE+4.7%
Maze Therapeutics, Inc.
VIR+5.3%
Vir Biotechnology, Inc.